elranatamab
pfizer
['magnetismm-3', 'mmsm', 'elranatamab']
congress #asco22 | presents the initial safety results of elranatamab s ph ii trial (magnetismm-3). no gr3 crs or icans observed; the 2-step-up priming regimen successfully mitigated the rate and severity of crs #mmsm 
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma